555 / 1631
Unmet need in iNHL – relapsed and refractory disease
1. The NHL Classification Project.
Blood
1997; 89:
3909–3918
2. Fowler NH.
Pharmacy and Therapeutics
2011; 36:
590–598
4. Horning SJ, et al.
J Clin Oncol
2005;23:712–719
5. Czuczman MS, et al.
Blood
2012;119:3698–704
0
Bendamustine
monotherapy
3
PFS (%)
100
80
60
40
20
1
2
Time (years)
Median PFS
9.3 months
0
Radioimmunoconjugate
(
131
I-tositumomab)
4
PFS (%)
100
80
60
40
20
1
2
Time (years)
Median PFS
10.4 months
0
Ofatumumab
monotherapy
5
100
80
60
40
20
1
2
Time (years)
Median PFS
5.8 months
PFS (%)
PFS (%)
1
2
100
80
60
40
20
0
Idelalisib monotherapy
6
Time (years)
Median PFS
11.0 months
Effective current treatment options limited, with no standard of care currently
identified